FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review.
Koch AL, Vellanki PJ, Drezner N, Li X, Mishra-Kalyani PS, Shen YL, Xia H, Li Y, Liu J, Zirkelbach JF, Palazov E, Gamarian A, Choo Q, Girčys A, Rohr UP, Fesenko N, Spillman D, Pazdur R, Beaver JA, Singh H.
Koch AL, et al. Among authors: fesenko n.
Clin Cancer Res. 2021 Dec 15;27(24):6638-6643. doi: 10.1158/1078-0432.CCR-21-1034. Epub 2021 Jul 22.
Clin Cancer Res. 2021.
PMID: 34301748
Clinical Trial.